Research programme: microbiome therapeutic - Galmed Pharmaceuticals/MyBiotics
Latest Information Update: 24 Nov 2020
At a glance
- Originator Galmed Pharmaceuticals; MyBiotics
- Class Antifibrotics; Bacteria; Hepatoprotectants
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Fibrosis; Non-alcoholic steatohepatitis